BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 12775708)

  • 1. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation.
    Martin LA; Farmer I; Johnston SR; Ali S; Marshall C; Dowsett M
    J Biol Chem; 2003 Aug; 278(33):30458-68. PubMed ID: 12775708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation.
    Martin LA; Farmer I; Johnston SR; Ali S; Dowsett M
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S75-84. PubMed ID: 16113101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation.
    Chan CM; Martin LA; Johnston SR; Ali S; Dowsett M
    J Steroid Biochem Mol Biol; 2002 Aug; 81(4-5):333-41. PubMed ID: 12361723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells.
    Jeng MH; Yue W; Eischeid A; Wang JP; Santen RJ
    Breast Cancer Res Treat; 2000 Aug; 62(3):167-75. PubMed ID: 11072781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling.
    Martin LA; Pancholi S; Chan CM; Farmer I; Kimberley C; Dowsett M; Johnston SR
    Endocr Relat Cancer; 2005 Dec; 12(4):1017-36. PubMed ID: 16322340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway.
    Ariazi EA; Kraus RJ; Farrell ML; Jordan VC; Mertz JE
    Mol Cancer Res; 2007 Jan; 5(1):71-85. PubMed ID: 17259347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways.
    Yue W; Wang JP; Conaway MR; Li Y; Santen RJ
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):265-74. PubMed ID: 14623520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells.
    Oh AS; Lorant LA; Holloway JN; Miller DL; Kern FG; El-Ashry D
    Mol Endocrinol; 2001 Aug; 15(8):1344-59. PubMed ID: 11463858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis.
    Filardo EJ; Quinn JA; Frackelton AR; Bland KI
    Mol Endocrinol; 2002 Jan; 16(1):70-84. PubMed ID: 11773440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
    Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
    Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estradiol rapidly activates Akt via the ErbB2 signaling pathway.
    Stoica GE; Franke TF; Wellstein A; Czubayko F; List HJ; Reiter R; Morgan E; Martin MB; Stoica A
    Mol Endocrinol; 2003 May; 17(5):818-30. PubMed ID: 12554767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of prolonged hydroxytamoxifen treatment of MCF-7 cells on mitogen activated kinase cascade.
    Rabenoelina F; Semlali A; Duchesne MJ; Freiss G; Pons M; Badia E
    Int J Cancer; 2002 Apr; 98(5):698-706. PubMed ID: 11920638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway.
    Stoica GE; Franke TF; Moroni M; Mueller S; Morgan E; Iann MC; Winder AD; Reiter R; Wellstein A; Martin MB; Stoica A
    Oncogene; 2003 Sep; 22(39):7998-8011. PubMed ID: 12970748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
    Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
    Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
    Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen-induced activation of the mitogen-activated protein kinase cascade in the cerebral cortex of estrogen receptor-alpha knock-out mice.
    Singh M; Sétáló G; Guan X; Frail DE; Toran-Allerand CD
    J Neurosci; 2000 Mar; 20(5):1694-700. PubMed ID: 10684871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
    Marsaud V; Gougelet A; Maillard S; Renoir JM
    Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.
    Hutcheson IR; Knowlden JM; Madden TA; Barrow D; Gee JM; Wakeling AE; Nicholson RI
    Breast Cancer Res Treat; 2003 Sep; 81(1):81-93. PubMed ID: 14531500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera.
    Chen D; Washbrook E; Sarwar N; Bates GJ; Pace PE; Thirunuvakkarasu V; Taylor J; Epstein RJ; Fuller-Pace FV; Egly JM; Coombes RC; Ali S
    Oncogene; 2002 Jul; 21(32):4921-31. PubMed ID: 12118371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
    Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
    PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.